Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

CAR T-cell therapy is a promising innovative therapy for hematological malignancies. Immune effectors cells-associated neurotoxicity syndrome (ICANS) is a significant complication of CAR therapy. The goal of this study is to understand what brain mechanisms become disrupted when patients experience ICANS. The study will test the hypothesis that cerebrospinal fluid catecholamines and multimodal magnetic resonance imaging are affected in this disorder. To test this hypothesis, the study will measure cerebrospinal fluid catecholamines in ICANS patients and evaluate brain magnetic resonance imaging for these participants. This study may contribute to knowledge about brain biomarkers and imaging of ICANS, which will greatly aid in ICANS detection and prevention.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Subjects must be ≥ 18 years of age at signing of informed consent.

• Subjects are scheduled to receive CAR T-cell treatment.

Locations
Other Locations
China
980th Hospital
RECRUITING
Shijiazhuang
Contact Information
Primary
Shoulong Zhang
longer_human007@126.com
86-0311-98224
Time Frame
Start Date: 2023-03-06
Estimated Completion Date: 2027-12
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: zhang shoulong
Collaborators: Jinan Military General Hospital, Changhai Hospital

This content was sourced from clinicaltrials.gov